CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4- amidinophenyl)furan-bis-O-methylamidoxime]

Drug Metabolism and Disposition

Volumn 34, Issue 12, 2006, Pages 1985-1994

  Wang, Michael Zhuo ^a   Saulter, Janelle Y ^a   Usuki, Etsuko ^b   Cheung, Yen Ling ^d   Hall, Michael ^d   Bridges, Arlene S ^a   Loewen, Greg ^b   Parkinson, Oliver T ^b   Stephens, Chad E ^c   Allen, James L ^e   Zeldin, Darryl C ^f   Boykin, David W ^c   Tidwell, Richard R ^a   Parkinson, Andrew ^b   Paine, Mary F ^a   Hall, James Edwin ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b XenoTech LLC   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

^d HUNTINGDON LIFE SCIENCES   (United Kingdom)

^e Immtech Pharmaceuticals Inc   (United States)

^f NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; 17 OCTADECYNOIC ACID; 2,5 BIS(4 AMIDINOPHENYL)FURAN; 2,5 BIS(4 AMIDINOPHENYL)FURAN BIS O METHYLAMIDOXIME; ALPHA NAPHTHOFLAVONE; ANTIPARASITIC AGENT; ARACHIDONIC ACID; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2J2; CYTOCHROME P450 4F; CYTOCHROME P450 4F2; CYTOCHROME P450 4F3B; CYTOCHROME P450 INHIBITOR; DB 289; EBASTINE; FLUVOXAMINE; FURAFYLLINE; FURAN DERIVATIVE; HET 0016; KETOCONAZOLE; N HYDROXY N' (4 N BUTYL 2 METHYLPHENYL)FORMAMIDINE; OMEPRAZOLE; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFAPHENAZOLE; THIOTEPA; TRIMETHOPRIM; UNINDEXED DRUG;

ANIMAL CELL; ARACHIDONIC ACID METABOLISM; ARTICLE; CATALYSIS; CONTROLLED STUDY; DEMETHYLATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANTIPARASITIC AGENTS; BENZAMIDINES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; PRODRUGS;

EID: 33751543062     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.010587     Document Type: Article

References (40)

1. Anbazhagan M, Saulter JY, Hall JE, and Boykin DW (2003) Synthesis of metabolites of the prodrug 2,5-bis(4-O-methoxyamidinophenyl)furan. Heterocycles 60:1133-1145.
2. Bell CA, Dykstra CC, Naiman NA, Cory M, Fairley TA, and Tidwell RR (1993) Structure-activity studies of dicationically substituted bis-benzimidazoles against Giardia lamblia: correlation of antigiardial activity with DNA binding affinity and giardial topoisomerase II inhibition. Antimicrob Agents Chemother 37:2668-2673.
3. Bell CA, Hall JE, Kyle DE, Grogl M, Ohemeng KA, Allen MA, and Tidwell RR (1990) Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis. Antimicrob Agents Chemother 34:1381-1386.
4. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832.
5. Boykin DW, Kumar A, Hall JE, Bender BC, and Tidwell RR (1996) Anti-pneumocystis activity of bis-amidoximes and bis-O-alkylamidoximes prodrugs. Bioorg Med Chem Lett 6:3017-3020.
6. Bylund J, Finnstrom N, and Oliw EH (1999) Gene expression of a novel cytochrome P450 of the CYP4F subfamily in human seminal vesicles. Biochem Biophys Res Commun 261:169-174.
7. Christmas P, Jones JP, Patten CJ, Rock DA, Zheng Y, Cheng SM, Weber BM, Carlesso N, Scadden DT, Rettie AE, et al. (2001) Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J Biol Chem 276:38166-38172.
8. Cui X, Nelson DR, and Strobel HW (2000) A novel human cytochrome P450 4F isoform (CYP4F11): cDNA cloning, expression, and genomic structural characterization. Genomics 68:161-166.
9. Das BP and Boykin DW (1977) Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans. J Med Chem 20:531-536.
10. Doshi M, Marcus C, Bejjani BA, and Edward DP (2006) Immunolocalization of CYP1B1 in normal, human, fetal and adult eyes. Exp Eye Res 82:24-32.
11. Fitzpatrick K, Midgley I, Henderson SJ, Taylor LM, Houchen TL, Wright SJ, McBurney A, John BA, Cybulski ZR, Hall JE, et al. (2004) Pharmacokinetics and metabolism of the prodrug DB289 in the rat and monkey and its conversion to the active entity, DB75. Drug Metab Rev 36:338-338.
12. Gelboin HV, Shou M, Goldfarb I, Yang TJ, and Krausz K (1998) Monoclonal antibodies to cytochromes P450. Methods Mol Biol 107:227-237.
13. Guengerich FP (2004) Human cytochrome P450 enzymes, in Cytochrome P450, Structure, Mechanism, and Biochemistry, 3rd ed (Ortiz de Montellano PR ed) pp 377-463, Plenum Publishers, New York.
14. Hall JE, Kerrigan JE, Ramachandran K, Bender BC, Stanko JP, Jones SK, Patrick DA, and Tidwell RR (1998) Anti-Pneumocystis activities of aromatic diamidoxime prodrugs. Antimicrob Agents Chemother 42:666-674.
15. Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, and Funae Y (2002) Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300:298-304.
16. Hashizume T, Mise M, Matsumoto S, Terauchi Y, Fujii T, Imaoka S, Funae Y, Kamataki T, and Miyazaki H (2001) A novel cytochrome P450 enzyme responsible for the metabolism of ebastine in monkey small intestine. Drug Metab Dispos 29:798-805.
17. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
18. Ito O, Nakamura Y, Tan L, Ishizuka T, Sasaki Y, Minami N, Kanazawa M, Ito S, Sasano H, and Kohzuki M (2006) Expression of cytochrome P-450 4 enzymes in the kidney and liver: regulation by PPAR and species-difference between rat and human. Mol Cell Biochem 284:141-148.
19. Jin R, Koop DR, Raucy JL, and Lasker JM (1998) Role of human CYP4F2 in hepatic catabolism of the proinflammatory agent leukotriene B4. Arch Biochem Biophys 359:89-98.
20. Kikuta Y, Kusunose E, and Kusunose M (2002) Prostaglandin and leukotriene omegahydroxylases. Prostaglandins Other Lipid Mediat 68-69:345-362.
21. Krausz KW, Goldfarb I, Yang TJ, Gonzalez FJ, and Gelboin HV (2000) An inhibitory monoclonal antibody to human cytochrome P450 that specifically binds and inhibits P4502C9II, an allelic variant of P4502C9 having a single amino acid change Arg144 Cys. Xenobiotica 30:619-625.
22. Kroetz DL and Xu F (2005) Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation. Annu Rev Pharmacol Toxicol 45:413-438.
23. Miyata N, Taniguchi K, Seki T, Ishimoto T, Sato-Watanabe M, Yasuda Y, Doi M, Kametani S, Tomishima Y, Ueki T, et al. (2001) HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol 133:325-329.
24. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, and Melvin WT (1997) Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57:3026-3031.
25. Paine MF, Schmiedlin-Ren P, and Watkins PB (1999) Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. Drug Metab Dispos 27:360-364.
26. Sarkis A, Lopez B, and Roman RJ (2004) Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr Opin Nephrol Hypertens 13:205-214.
27. Saulter JY, Kurian JR, Trepanier LA, Tidwell RR, Bridges AS, Boykin DW, Stephens CE, Anbazhagan M, and Hall JE (2005) Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase. Drug Metab Dispos 33:1886-1893.
28. Scarborough PE, Ma J, Qu W, and Zeldin DC (1999) P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev 31:205-234.
29. Steck EA, Kinnamon KE, Rane DS, and Hanson WL (1981) Leishmania donovani, Plasmodium berghei, Trypanosoma rhodesiense: antiprotozoal effects of some amidine types. Exp Parasitol 52:404-413.
30. Stephens CE, Patrick DA, Chen HD, Tidwell RR, and Boykin DW (2001) Synthesis of deuterium-labeled 2,5-bis(4-amidinophenyl)furan, 2,5-bis[4-(methoxyamidino)phenyl]furan, and 2,7-diamidinocarbazole. J Labelled Compd Radiopharm 44:197-208.
31. Tidwell RR, Jones SK, Geratz JD, Ohemeng KA, Bell CA, Berger BJ, and Hall JE (1990) Development of pentamidine analogues as new agents for the treatment of Pneumocystis carinii pneumonia. Ann NY Acad Sci 616:421-441.
32. Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, and Schwartzman ML (1998) Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 284:966-973.
33. Wu S, Moomaw CR, Tomer KB, Falck JR, and Zeldin DC (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460-3468.
34. Xiao YF, Ke Q, Seubert JM, Bradbury JA, Graves J, Degraff LM, Falck JR, Krausz K, Gelboin HV, Morgan JP, et al. (2004) Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2. Mol Pharmacol 66:1607-1616.
35. Yeates C (2003) DB-289 Immtech International. IDrugs 6:1086-1093.
36. Yeramian P, Meshnick SR, Krudsood S, Chalermrut K, Silachamroon U, Tangpukdee N, Allen J, Brun R, Kwiek JJ, Tidwell R, et al. (2005) Efficacy of DB289 in Thai patients with Plasmodium vivax or acute, uncomplicated Plasmodium falciparum infections. J Infect Dis 192:319-322.
37. Zhou L, Lee K, Thakker DR, Boykin DW, Tidwell RR, and Hall JE (2002) Enhanced permeability of the antimicrobial agent 2,5-bis(4-amidinophenyl)furan across Caco-2 cell monolayers via its methylamidoidme prodrug. Pharm Res (NY) 19:1689-1695.
38. Zhou L, Thakker DR, Voyksner RD, Anbazhagan M, Boykin DW, Hall JE, and Tidwell RR (2004) Metabolites of an orally active antimicrobial prodrug, 2,5-bis(4-amidinophenyl)furanbis-O-methylamidoxime, identified by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 39:351-360.
39. Zimmerlin AG and Patten CJ (2000) Role of CYP4F in the metabolic clearance of FTY720 - prediction of low drug to drug interaction potential. Transplantation 69:S191.
40. Zou AP, Ma YH, Sui ZH, Ortiz de Montellano PR, Clark JE, Masters BS, and Roman RJ (1994) Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid omega-hydroxylase, on renal function in rats. J Pharmacol Exp Ther 268:474-481.